Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1962 1
1966 1
1970 3
1972 1
1973 1
1974 1
1975 7
1976 8
1977 11
1978 10
1979 10
1980 16
1981 23
1982 13
1983 23
1984 26
1985 18
1986 33
1987 24
1988 28
1989 23
1990 24
1991 35
1992 41
1993 43
1994 37
1995 36
1996 42
1997 40
1998 51
1999 62
2000 51
2001 52
2002 50
2003 49
2004 74
2005 73
2006 66
2007 77
2008 86
2009 76
2010 78
2011 82
2012 101
2013 108
2014 116
2015 110
2016 119
2017 105
2018 127
2019 132
2020 161
2021 192
2022 186
2023 202
2024 79

Text availability

Article attribute

Article type

Publication date

Search Results

2,945 results

Results by year

Filters applied: . Clear all
Page 1
Interventions for myopia control in children: a living systematic review and network meta-analysis.
Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R, Verkicharla PK, Li D, Mavi S, Kernohan A, Li T, Walline JJ. Lawrenson JG, et al. Cochrane Database Syst Rev. 2023 Feb 16;2(2):CD014758. doi: 10.1002/14651858.CD014758.pub2. Cochrane Database Syst Rev. 2023. PMID: 36809645 Free PMC article. Review.
Critical outcomes were progression of myopia (defined as the difference in the change in spherical equivalent refraction (SER, dioptres (D)) and axial length (mm) in the intervention and control groups at one year or longer) and difference in the change in SER and axial length fo …
Critical outcomes were progression of myopia (defined as the difference in the change in spherical equivalent refraction (SER, dioptres (D)) …
An explanation for SARS-CoV-2 rebound after Paxlovid treatment.
Perelson AS, Ribeiro RM, Phan T. Perelson AS, et al. medRxiv [Preprint]. 2023 Jun 1:2023.05.30.23290747. doi: 10.1101/2023.05.30.23290747. medRxiv. 2023. PMID: 37398088 Free PMC article. Preprint.
In a fraction of SARS-CoV-2 infected individuals treated with the oral antiviral Paxlovid, the virus rebounds following treatment. The mechanism driving rebound is not understood. ...Finally, the models are used to test the therapeutic effects of two alternat …
In a fraction of SARS-CoV-2 infected individuals treated with the oral antiviral Paxlovid, the virus rebounds following treatment. Th …
Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report.
Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BHK, Young AL, Tham CC, Chen LJ, Pang CP. Yam JC, et al. Ophthalmology. 2022 Mar;129(3):308-321. doi: 10.1016/j.ophtha.2021.10.002. Epub 2021 Oct 7. Ophthalmology. 2022. PMID: 34627809 Clinical Trial.
Older age and lower concentration were associated with smaller rebound effects in both SE progression (P < 0.001) and AL elongation (P < 0.001). ...Stopping treatment at an older age and lower concentration are associated with a smaller rebound....

Older age and lower concentration were associated with smaller rebound effects in both SE progression (P < 0.001) and AL elongatio

…
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022.
Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. Wang L, et al. medRxiv [Preprint]. 2022 Jun 22:2022.06.21.22276724. doi: 10.1101/2022.06.21.22276724. medRxiv. 2022. PMID: 35794889 Free PMC article. Preprint.
The Centers for Disease Control and Prevention (CDC) has recently issued a Health Alert Network Health Advisory to update the public on the potential for COVID-19 rebound after Paxlovid treatments. However, the rates of COVID-19 rebound in a real-world population or …
The Centers for Disease Control and Prevention (CDC) has recently issued a Health Alert Network Health Advisory to update the public on the …
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
Kunz D, Dauvilliers Y, Benes H, García-Borreguero D, Plazzi G, Seboek Kinter D, Coloma P, Rausch M, Sassi-Sayadi M, Thein S. Kunz D, et al. CNS Drugs. 2023 Jan;37(1):93-106. doi: 10.1007/s40263-022-00980-8. Epub 2022 Dec 9. CNS Drugs. 2023. PMID: 36484969 Free PMC article. Clinical Trial.
Daridorexant did not induce next-morning sleepiness and no withdrawal-related symptoms or rebound were observed after treatment discontinuation. Improvements in sleep and daytime functioning were maintained through to the end of the study and were most pronounced with dari …
Daridorexant did not induce next-morning sleepiness and no withdrawal-related symptoms or rebound were observed after treatment disco …
Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
Yardley J, Kärppä M, Inoue Y, Pinner K, Perdomo C, Ishikawa K, Filippov G, Kubota N, Moline M. Yardley J, et al. Sleep Med. 2021 Apr;80:333-342. doi: 10.1016/j.sleep.2021.01.048. Epub 2021 Feb 1. Sleep Med. 2021. PMID: 33636648 Free article. Clinical Trial.
RESULTS: For all sleep parameters, the significant benefits observed with LEM5 and LEM10 versus placebo over six months were maintained at twelve months in subjects who received twelve continuous months of treatment. There was no evidence of rebound insomnia or withdrawal …
RESULTS: For all sleep parameters, the significant benefits observed with LEM5 and LEM10 versus placebo over six months were maintained at t …
Calcium and acid rebound: a reappraisal.
Hade JE, Spiro HM. Hade JE, et al. J Clin Gastroenterol. 1992 Jul;15(1):37-44. doi: 10.1097/00004836-199207000-00010. J Clin Gastroenterol. 1992. PMID: 1500660 Review.
We review acid rebound, the seemingly paradoxical increase in acid secretion resulting from administration of an antacid. ...Other antacids, notably magnesium hydroxide and aluminum hydroxide, may therefore also cause rebound, but the data in this area are less conv …
We review acid rebound, the seemingly paradoxical increase in acid secretion resulting from administration of an antacid. ...Other an …
Neural excitatory rebound induced by valproic acid may predict its inadequate control of seizures.
Zou X, Zhu Z, Guo Y, Zhang H, Liu Y, Cui Z, Ke Z, Jiang S, Tong Y, Wu Z, Mao Y, Chen L, Wang D. Zou X, et al. EBioMedicine. 2022 Sep;83:104218. doi: 10.1016/j.ebiom.2022.104218. Epub 2022 Aug 12. EBioMedicine. 2022. PMID: 35970021 Free PMC article.
The relationship between seizure control and the excitatory rebound was further determined by diagnostic test and univariate analysis. ...Computational simulation experiments revealed that inhibitory power-induced excitatory rebound is an intrinsic feature in …
The relationship between seizure control and the excitatory rebound was further determined by diagnostic test and univariate a …
Determinants of Adiposity Rebound Timing in Children.
Ip EH, Marshall SA, Saldana S, Skelton JA, Suerken CK, Arcury TA, Quandt SA. Ip EH, et al. J Pediatr. 2017 May;184:151-156.e2. doi: 10.1016/j.jpeds.2017.01.051. Epub 2017 Feb 24. J Pediatr. 2017. PMID: 28242030 Free PMC article.
OBJECTIVE: Adiposity rebound (AR) or BMI (body mass index) rebound refers to the increase in BMI following the minimum BMI in early childhood. ...BMI was plotted serially for each child and the onset of BMI rebound was determined by visual inspection of the g …
OBJECTIVE: Adiposity rebound (AR) or BMI (body mass index) rebound refers to the increase in BMI following the minimum BMI in …
2,945 results